SCHEMBL4602865

SCHEMBL4602865

CCC(NC(=O)c1c(C)c(-c2ccccc2)nc2ccccc12)c1cccnc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 20/20 0.82
TACR2 P21452 6/20 0.82
CYP1A2 P05177 2/20 0.82
CYP3A4 P08684 2/20 0.82
CYP2C9 P11712 2/20 0.82
CYP2C19 P33261 2/20 0.82
MEN1 O00255 1/20 0.82
ALDH1A1 P00352 1/20 0.82
TP53 P04637 1/20 0.82
TSHR P16473 1/20 0.82
NFKB1 P19838 1/20 0.82
MAPK1 P28482 1/20 0.82
BLM P54132 1/20 0.82
PMP22 Q01453 1/20 0.82
KMT2A Q03164 1/20 0.82
ATM Q13315 1/20 0.82
SMN1; SMN2 Q16637 1/20 0.82
HIF1A Q16665 1/20 0.82
FFAR4 Q5NUL3 1/20 0.82
NPSR1 Q6W5P4 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sb-222200 SCHEMBL29407508 0.91 TACR3 (1.00) TACR3TACR2CYP1A2CYP3A4CYP2C9
Sb-222200 SCHEMBL1580886 0.91 TACR3 (1.00) TACR3TACR2CYP1A2CYP3A4CYP2C9
Sb-222200 SCHEMBL6448819 0.91 TACR3 (1.00) TACR3TACR2CYP1A2CYP3A4CYP2C9
Sb-222200 SCHEMBL3105312 0.91 TACR3 (1.00) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL14094502 0.90 TACR3 (0.82) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL14094501 0.90 TACR3 (0.82) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL4602530 0.89 TACR3 (0.88) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL14094503 0.87 TACR3 (0.83) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL14094506 0.87 TACR3 (0.64) TACR3TACR2CYP1A2CYP3A4CYP2C9
SCHEMBL19249849 0.85 TACR3 (0.89) TACR3TACR2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915362-A1 AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS AstraZeneca AB (SE) 2008-04-30 EP claimed
WO-2007018465-A1 AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO claimed
US-20080200504-A1 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide ASTRAZENECA AB (SE) 2008-08-21 US disclosed
US-20080200504-A1 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide ASTRAZENECA AB (SE) 2008-08-21 US disclosed
WO-2007018465-A1 AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200504-A1 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide NPY4R, PROKR1, NPSR1 TACR3 41/4885TACR2 22/4885CYP1A2 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.